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Abstract
Purpose—Single nucleotide polymorphisms in angiotensinogen at positions -20 and -6 are 
associated with increased severity and progression of various fibrotic diseases. Our earlier work 
demonstrated that the progression of Idiopathic Pulmonary Fibrosis was associated with the A-6 
allele. This study examined the hypothesis that the homozygous CC genotype at -20 and the AA 
genotype at -6 would confer worse measures of pulmonary function (measured by pulmonary 
function tests) in Idiopathic Pulmonary Fibrosis.
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Method—Multiple logistic regression analysis was applied to a NIH Lung Tissue Research 
Consortium cohort and Spanish cohort, while also adjusting for covariates to determine the effects 
of these SNPs on measures of pulmonary function.
Results—Analysis demonstrated that the CC genotype at -20 was strongly associated with 
reduced diffusing capacity in males in both cohorts (p = 0.0028 for LTRC and p = 0.017). In 
females, the AA genotype was significantly associated with lower FVC (p = 0.0082) and Valv (p = 
0.022). In males, the haplotype CA at -20 and -6 in AGT was also strongly associated with 
reduced diffusing capacity in both cohorts.
Conclusions—This study is the first to demonstrate an association of angiotensinogen 
polymorphisms (-20A>C and -6G>A) with lower measures of pulmonary function in Idiopathic 
Pulmonary Fibrosis. It is also the first to relate the effect of gender in lung fibrosis with 
polymorphisms in angiotensinogen.
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INTRODUCTION
Idiopathic pulmonary fibrosis (IPF) is the most common form of interstitial lung disease. It 
is a “chronic, progressive, and irreversible” condition with a bias towards males and people 
in their fifth through eighth decade of life [1]. Upon diagnosis, the mean survival is three 
years. Currently, the only therapy to prolong survival is lung transplantation [1]. However, 
the five year post-operative survival rate is 44% [1] The current modes of therapy 
(corticosteroids and immunosuppressants) are of minimal benefit to IPF patients. This 
reflects the incomplete knowledge underlying the pathogenesis of IPF and paves way for 
novel therapies to address this void [2].
A strong predictor of mortality in IPF is the number of myofibroblastic foci [3]. 
Myofibroblasts play an important role in lung fibrosis. They can be derived from a variety of 
sources including pericytes, fibrocytes, epithelial or endothelial cells, and normal lung 
fibroblasts, which when stimulated with transforming growth factor (TGF)-β1 differentiate 
into myofibroblasts. Myofibroblasts within many tissues are a known source of collagen and 
angiotensin II (ANGII), and the ANGII produced by myofibroblasts is known to mediate 
fibrogenesis in various organ systems such as the heart, kidney, liver, pancreas, skin, and 
lung [4-10]. ANGII is derived from its precursor angiotensinogen (AGT), and both AGT and 
ANGII have been shown by this laboratory to be required for experimental lung fibrosis 
[11-12]. ANGII also enhances TGF-β1 synthesis in human lung myofibroblasts isolated from 
patients with IPF [9]. In turn, TGF-β1 is able to stimulate AGT transcription in 
myofibroblasts, thus creating an “ANGII-TGF- 1 autocrine loop” in myofibroblasts. 9 This 
laboratory also demonstrated that TGF-β1 inducible AGT transcription is regulated through 
two transcription factors, JunD and HIF-1α, both of which act on binding domains in the 
core promoter of AGT in the region spanning from –46 to +22 from the transcription start 
site [13].
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The core promoter also contains three single nucleotide polymorphisms (SNPs) located at 
-20, -18, and -6. The SNPs at these locations have been shown to result in changes in AGT 
transcription rate in non-pulmonary cell types. In hepatocytes, the presence of the CC 
haplotype at -20 and -18 respectively, increased AGT transcription to more than two-fold 
when compared to the AT haplotype [14]. Similarly, the presence of the A allele at -6 
increased AGT transcription in comparison to the G allele at the same locus [15]. These 
SNPs have also been associated with the severity and/or progression of various diseases 
including IgA nephropathy, hepatic fibrosis and cirrhosis, hypertension, and IPF [16-21]. In 
a Spanish IPF cohort, our lab demonstrated that the AA genotype of -6G>A was 
significantly associated with disease progression as measured by alveolar-arterial oxygen 
gradient over time [20].
On this basis, it was hypothesized here that the presence of CC genotype at -20 and/or the 
AA genotype at -6, particularly when found together, would confer lower measures of 
pulmonary function in IPF as measured by pulmonary function tests (PFTs). In accord with 
this hypothesis, it was theorized that the presence of both of these alleles would confer a 




The Lung Tissue Research Consortium (LTRC) provided 163 blood samples and over 1100 
associated clinical variables from IPF patients. From these, samples that were unable to be 
genotyped and samples that were missing variables of interest were excluded. The final pool 
consisted of 149 samples and 68 variables of interest that came from the categories of 
demographics, tobacco use, environmental exposure, disease history, medications, 
pulmonary function tests, and arterial blood gases. This pool was composed of 94 males and 
55 females (mean ± SD age: 63.4 ± 8.5 and 62.4 ± 9.2 respectively). Similar analyses were 
performed on a second cohort consisting of 203 patients from a Spanish population. This 
group was composed of 123 males and 80 females (mean ± SD age: 66.1 ± 10.6 and 67.5 ± 
13.1 respectively).
Genotyping polymorphisms at -20 and -6
The genotyping protocol was derived from Jeunemaitre et al. with modifications in primer 
design [22]. The primers utilized were 5′- GTC GCT TCT GGC ATC TGT CC -3′ (forward) 
and 5′- CCT TTT CCT CCT AGC CCA CA -3′ (reverse). A salting procedure was used to 
extract genomic DNA from peripheral leukocytes (23). Each sample was subjected to the 
following PCR cycling conditions: 94°C for 5 minutes, followed by 35 cycles, each at 94°C 
for 30 seconds, 63°C for 30 seconds, and 72°C for 45 seconds, with a final extension at 
72°C for 7 minutes. Each reaction was performed in a 20 μL volume containing 0.5U Taq 
polymerase (Promega Corp, Madison, WI), 1.5 mM MgCl2, 0.2 mMdNTPs, 0.1 μg/
μLPuregeneRNAse A Solution (Gentra Systems, Minneapolis, MN), and 1 μM of each 
primer. The amplification of each product was checked on a 2% agarose gel using 5 μL of 
the PCR product. If amplification was sufficient, the remaining 15 μL underwent a 
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purification step to remove contaminating primers and dNTPs. The purification step 
consisted of adding 0.45 μL (5 U/μL) of Antarctic Phosphatase (New England Biolabs), 1.5 
μL of 10x Antarctic Phosphatase buffer (New England Biolabs), and 0.225 μL (10 U/μL) of 
Exonuclease I (USB). This mixture was incubated at 37°C for 30 minutes followed by a 20 
minute incubation at 80°C. Sequencing was performed using 2 μL of purified PCR product, 
9.7 μL of water, and 0.3 μL (100 μM) of primer. Both forward and reverse primers were 
utilized in separate reactions and sequenced on an ABI Prism 3700 DNA Analyzer at the 
Research Technology Support Facility at Michigan State University. The results were 
analyzed using the program, Sequencher v4.7(Gene Codes Corp., Ann Arbor, MI) to 
determine SNPs rs 5050 (-20G>A) and rs 5051 (-6A>C) located in the promoter of AGT.
Statistical Analysis
The relationship between measures of pulmonary function (as measured by PFTs including 
FEV1, FVC, FEV6, mean DLCO, Valv, and KCO) and the genotyped SNPs at -20 and -6 was 
tested by fitting regression models assuming different gene action modes (i.e., additive, 
dominance and recessive) after adjusting for the effects of covariates. Data analysis was 
done with statistical software R (2.13.2 version). From the original 163 individuals, the pool 
of 149 individuals was included for analysis after exclusion of samples that were unable to 
be genotyped and those in which variables of interest were missing. To account for possible 
gender differences in disease progression, missing phenotypic values were imputed using 
the mean value of the corresponding phenotype for male and female data separately. 
Analysis for the Spanish cohort was similar except for the inclusion of covariates (due to the 
lack of collection of these variables).
All the phenotypes (as measured by PFTs) were individually analyzed. A stepwise variable 
selection was initially performed on all covariates for each phenotype in R. The selected 
covariates were then fitted into the genetic models (Table S1) together with the SNP 
variables. For each phenotype, roughly ten to fifteen covariates were left after variable 
selection. Three genetic models representing different gene action modes were considered in 
this study (the joint model analyzing the whole population in Table S1). In practice, the true 
disease model is unknown. Statistically, a model selection criterion can be used to choose 
which genetic model fits the data best. The Akaike information criterion (AIC) was chosen 
to select the optimal model, which is defined as AIC = -2logL + 2k, where L is the 
regression likelihood and k is the total number of parameters fitted in the model. The one 
with the minimum AIC value is chosen as the optimal one. For the three models, testing a 
SNP effect is equivalent to testing H0: β1 = β12 = 0, a 2 degrees of freedom (df) likelihood 
ratio test, while adjusting for the effects of other covariates. The likelihood ratio statistic 
asymptotically follows a chi-square distribution with 2 df. For each phenotype, multiple 
testing adjustment was done for the two loci. Thus any SNP with a p-value < 0.025 was 
considered statistically significant by maintaining a family-wise error rate of 0.05. To assess 
if male and female populations have different genetic bases in determining worse measures 
in pulmonary functions, the above models were modified by removing the sex covariate as 
well as the genetic-by-sex interaction term (the sex-specific model in Table S1) and were 
fitted to the male and female data separately. The same set of covariates fitted with the male 
and female combined data was fitted into the modified models. Likelihood ratio test was 
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applied to test the significance of the regression coefficients after selecting the optimal 
model by the AIC criterion. A power study revealed that the datasets have more than 90% 
power to detect a mean difference larger than 0.7 between the largest and smallest means 
among the three genotype groups with a sample size of 55, the smallest sample size (for 
female in the LTRC cohort).
RESULTS
Characteristics of the patient population
Table 1a and 1b summarizes the age and mean pulmonary function test values for the LTRC 
and Spanish population subjects for which all genotyping and function test data were 
available. The data are separated by gender in accord with the finding of gender-specific 
differences in the association between AGT genotype and PFT values to be discussed below. 
No statistically significant differences were observed between males and females in any of 
the data reported in Table 1.
Genotype and allele frequencies
The genotype and allele frequencies for the -20A>C and -6G>A polymorphisms in AGT are 
summarized in Tables 2 and 3. No statistically significant differences were observed in the 
allele frequencies at either the -20 or -6 loci between men and women (Table 3).
Influence of AGT genotype on pulmonary function tests- whole population analysis
In an analysis of each cohort s a whole (Table 4, i.e. without separation by gender), the CC 
genotype at -20 was most strongly associated with reduction of KCO in both cohorts. 
However, the impact of gender on this measure was also significant (see below). The AA 
genotype at -6 also associated with reduction of KCO. In the LTRC cohort, gender did not 
influence this measure. Table 4 lists only those PFT data for which statistically significant 
differences were observed in this analysis.
Influence of AGT genotype on pulmonary function tests- gender-specific analyses
When the whole population was reanalyzed with sample separation on the basis of gender, 
several gender-specific effects of AGT genotype on PFT values were revealed. In the male 
IPF population (Table 5a), the CC genotype at the -20 locus was associated with a very 
strong reduction in KCO (from 3.19 ± 0.84 to 1.46 ± 0.34) of high statistical significance (p 
= 0.0028) in the LTRC cohort. This effect was also seen in the Spanish cohort [Table 5b (p 
= 0.017)]. The AA genotype at -6 also associated with reduced KCO in males, but with 
lower statistical significance (p=0.0214) in the LTRC cohort.
In females (Table 6), significant associations were only seen at the -6 locus. The -20 locus 
had no apparent effect. The AA genotype at -6 was associated with a reduction in FVC ( p = 
0.0081) and Valv (p = 0.022) in the LTRC cohort. However, in the Spanish cohort, this 
genotype was associated with an increase in diffusing capacity (p = 0.023). ). As discussed 
further below, the lack of decrease in KCO may be related to the large decrease in Valv 
associated with the AA genotype at -6 in females (p = 0.022).
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Analysis of an “IPF risk haplotype”
Multiple loci analysis revealed that in males, the AGT haplotype CA (at -20 and -6, 
respectively) was strongly associated with reduced KCO in both the LTRC cohort (p = 
0.0048) and the Spanish cohort (p = 0.014). This association was not statistically significant 
in females. Interestingly, the AG haplotype at -20 and -6 also was associated with reduced 
KCO in males, but at lower statistical significance (p=0.031) in the LTRC cohort. When the 
male and female combined data were analyzed, no significant haplotype was found.
DISCUSSION
The influence of AGT genotype on pulmonary function tests in IPF
Given that diffusing capacity for carbon monoxide is the best noninvasive clinical measure 
of the thickness of the alveolar-capillary diffusion barrier, it was theorized that diffusing 
capacity would be decreased the most in individuals with AGT genotypes already associated 
with hypertension and/or higher rates of AGT transcription in other organs. In males with 
IPF, this proved to be the case; the lowest KCO values were observed in individuals with the 
genotypes CC at -20 and AA at -6. The most drastic decrease was observed with the CC 
genotype at -20, with which the KCO decreased more than two-fold compared to the AA 
genotype (table 5). In males, FEV1 and FVC also increased, rather than decreased, with the 
CC genotype at the -20 locus; this might be due to more forceful expirations assisted by the 
increased elastic recoil imparted by the fibrotic lung parenchyma. Unfortunately, it is not 
possible to explore this hypothesis further with the LTRC dataset. Regardless, in females 
with IPF the lowest FVC and Valv values and highest KCO were observed in individuals 
with the AA genotype at -6 (table 6). These data are consistent with our earlier observations 
[21].
Influence of gender on the effects of the -20 and -6 loci on PFTs in IPF
IPF is known to affect more men than women, but little is known about the cause of this 
gender difference. This study is the first to report an association with gender of genetic 
variants in AGT at the -20 and -6 loci at both the genotype and haplotype level. On the 
genotype level, the male gender had a stronger effect at the -20 locus, while the female 
gender imparted a greater effect at the -6 locus. Other authors studying non-pulmonary 
systems have also observed gender-specific effects of AGT variants; for example, Chapman 
et al. demonstrated that the -6 locus was also more significantly associated with increased 
carotid intimal medial thickening in the female population [25]. In the present study, 
haplotype analysis revealed that the IPF “risk haplotype” CA was significant only in males 
(the AG haplotype was also significant but to a lesser degree). Although other authors have 
noted an additional, albeit rare, SNP in AGT at the -18 position [14]. The -18 locus was 
genotyped here but was not analyzed further due to the lack of this variant in the LTRC or 
Spanish cohorts.
AGT promoter sequence variants and transcription rate
In studies of AGT synthesis by isolated human hepatocytes, SNPs at the -20 and -6 loci 
influence the transcription rate of AGT mRNA [14-15]. The transcription rate is higher with 
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the C allele at -20 and the A allele at -6. In earlier studies of both animal models of lung 
fibrosis and isolated lung cells, transcription of the AGT gene has been shown to be required 
for the fibrogenic response to bleomycin and for the apoptotic response of alveolar epithelial 
cells to a number of profibrotic stimuli [9,12]. Taken together, these findings suggest, and 
indeed had lead us to hypothesize, that higher rates of AGT transcription in lung cells 
imparted by the CA haplotype would lead to worse lung fibrosis in IPF patients as indicated 
by reductions in KCO, DLCO or FVC. As discussed above, most of these effects were found 
in this study, but in a surprising gender-dependent manner.
Possible mechanisms underlying gender-specific effects of AGT sequence variants
Hormonal regulatory elements located in the same AGT promoter domain as the SNPs 
studied here also influence the transcription rate of AGT. Of particular interest is the 
estrogen response element that is located in the AGT promoter region spanning – 11 to – 25 
[26]. Estrogen receptor alpha (ER-α) preferentially binds to the -20 locus if the A nucleotide 
is present, and induces an increase in AGT transcription by human liver cells [26]. Estrogen 
also mediates fibrogenesis by up-regulating the transcription of procollagen I and TGF-β1 
[27]. TGF-β1 stimulates fibroblasts to transition into myofibroblasts, which in turn deposit 
collagen and express AGT constitutively [9, 13]. Another potential mechanism that might 
regulate AGT differentially by gender is the possibility that estrogen receptor binding to the 
AGT promoter prevents the binding of other transcription factors that might otherwise up- or 
down-regulate AGT transcription.
Conversely, the binding domain of the orphan receptor Arp-1 shares homology to the 
binding domain for ER-α [28]. The binding of Arp-1 to this domain reduces estrogen-
induced AGT transcription [28]. These data suggest that the balance between estrogen and 
Arp-1 at the -20 locus may thus be an influential factor in this gender discrimination. In 
males, it is possible that the balance may favor estrogen-induced AGT transcription instead 
of repression by Arp-1. IPF affects people in their fifth to eighth decade of life, and women 
in these decades tend to be in the post-menopausal stage. In this stage estrogen levels drop, 
and this may explain the bias for males at the -20 locus. In males with IPF, the KCO 
decreased with the presence of CC genotype at -20, while in females there was an increase 
in the KCO at this same locus. Thus, the balance between ER-α and Arp-1 may play a role 
in this difference, and this topic will be an interesting issue for future investigation.
Another possible explanation for this gender difference is the potential role of androgens in 
AGT transcription. Throughout the human lifespan, androgen receptors (AR) are expressed 
in both mesenchymal and epithelial cells. In studies of the prostate gland, ANGII enhanced 
the expression of AR through the ANGII type-1 receptor [29], and one of the down-stream 
effects of this cascade is prostate cell proliferation. If this model is applicable to the lung, 
modulation of androgen receptors might also contribute to increased severity of IPF in 
males. For these reasons, the potential role of androgens in the gender differences that AGT 
variants exert on IPF severity will also be an interesting topic for further research.
In this regard it is important to note that if comparisons are made of human, mouse and rat 
AGT promoter sequences, there is relatively low homology between these species in the 
TGF-β1-responsive domain of AGT between the TATA box and the transcription initiation 
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site [13]. Due to these sequence differences, human lung cells in culture should remain an 
important model to complement and extend the studies reported here. Moreover, caution 
should be exercised in attempts to extrapolate data on the regulation of AGT expression 
obtained from animal models to human lung fibrosis.
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Table 1
Mean values for variables of interest in the LTRC population and Spanish cohorts.
LTRC SPANISH
CHARACTERISTICS
2 MALES (n = 94) FEMALES (n = 55) MALES (n = 123) FEMALES (n = 80)
AGE (years) 63.4 ± 8.5 62.4 ± 9.2 66.1 ± 10.6 67.5 ± 13.1








FEV1/FVC (%) 82.7 ± 6.4 83.4 ± 7.2 ------ ------
FEV6 (L) 2.8 ± 0.7 2.0 ± 1.0 ------ ------
PEF (L·s-1) 8.5 ± 2.2 6.0 ± 1.6 ------ ------
TLC (% predicted) ------ ------ 70.5 ± 14.1 69.8 ± 15.7
PAO (mm Hg) ------ ------ 71.7 ± 12.8 73.3 ± 14.1




Valv (L) 3.9 ± 0.9 3.0 ± 0.6




1 Data are presented as mean ± SD.
2
Abbreviations are as follows: FEV1 = forced expiratory volume in one second; FVC = forced vital capacity; FEV6 = forced expiratory volume in 
six seconds; PEF = peak expiratory flow; ; TLC = total lung capacity; PAO = alveolar-arterial oxygen tension difference; DLCO = diffusing 
capacity of the lung for carbon monoxide; Valv = alveolar volume; KCO = ratio between DLCO and alveolar volume. 1 mm Hg = 0.133 kPa.
*
Units are defined as % predicted.
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Table 5
Mean values for pulmonary function tests in the male population at the -20 and -6 loci in the LTRC and 
Spanish cohorts.
1
-20 AGT SNP in male LTRC Cohort
PHENOTYPE AA AC CC P-VALUE
FEV1 (L) 2.21 ± 0.52 2.47 ± 0.65 2.75 ± 0.21 0.0217 (M1)
FEV6 (L) 2.65 ± 0.55 2.95 ± 0.78 3.45 ± 0.35 0.012 (M1)
FVC (L) 2.71 ± 0.64 2.99 ± 0.56 3.45 ± 0.07 0.019 (M1)
KCO (mL·min-1·mmHg-1·L-1) 3.19 ± 0.84 3.04 ± 0.96 1.46 ± 0.34 0.0028 (M1)
-20 AGT SNP in male Spanish Cohort
PHENOTYPE AA AC CC P-VALUE
DLCO (% predicted) 57.4 ± 12.3 52.5 ± 16.9 51.6 ± 7.1 0.05 (M3)
KCO (% predicted) 81.3 ± 20.4 72.0 ± 21.2 73.4 ± 9.8 0.017 (M3)
-6 AGT SNP in male LTRC Cohort
GG GA AA P-VALUE
KCO (mL·min-1·mmHg-1·L-1) 3.23 ± 0.85 3.06 ± 0.96 3.05 ± 1.1 0.021 (M3)
-6 AGT SNP in male Spanish Cohort
PHENOTYPE AA AC CC P-VALUE
------ ------ ------ ------ ------
1
Data are presented as mean ± SD. Significant results are accepted with p < 0.025 (with Bonferroni correction).
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Table 6
Mean values for pulmonary function tests in the female population at the -20 and -6 loci in the LTRC and 
Spanish cohorts.
1
-20 AGT SNP in female LTRC and Spanish Cohort
PHENOTYPE AA AC CC P-VALUE
------ ------ ------ ------ ------
-6 AGT SNP in female LTRC Cohort
GG GA AA P-VALUE
FVC (L) 2.08 ± 0.58 2.19 ± 0.50 1.38 ± 0.33 0.0082 (M2)
VALV (L) 3.27 ± 0.54 3.20 ± 0.54 2.50 ± 0.69 0.022 (M2)
-6 AGT SNP in female Spanish Cohort
GG GA AA P-VALUE
DLCO (% predicted) 58.1 ± 15.9 56.4 ± 17.3 69.1 ± 13.4 0.011 (M2)
KCO (% predicted 77.7 ± 18.2 78.4 ± 20.2 90.6 ± 15.0 0.023 (M2)
1
Data are presented as mean ± SD. Significant results are accepted with p < 0.025 (with Bonferroni correction).
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